← Back to patent-cliff list
Atamparib
Tier C — Watch / tradeAtamparib
Ribon Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PARP-7
Indications (approved)：Non-small cell lung cancer, Solid tumour
Regional status
US
Phase II
2022-03-15
EU
Phase II
2022-03-15
China
Phase II
2026-03-18
Japan
Phase I
2021-12-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Atamparib?
Approved indications include: Non-small cell lung cancer, Solid tumour.
When does the Atamparib patent expire?
No public expiry year is available for Atamparib yet; this page updates once verified.
How do I get a quote for Atamparib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05